# HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)

> **NCT03759379** · PHASE3 · COMPLETED · sponsor: **Alnylam Pharmaceuticals** · enrollment: 164 (actual)

## Conditions studied

- Amyloidosis, Hereditary
- Transthyretin Amyloidosis

## Interventions

- **DRUG:** Patisiran
- **DRUG:** Vutrisiran

## Key facts

- **NCT ID:** NCT03759379
- **Lead sponsor:** Alnylam Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-14
- **Primary completion:** 2020-11-10
- **Final completion:** 2025-11-05
- **Target enrollment:** 164 (ACTUAL)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03759379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03759379, "HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03759379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*